Pathogenesis of bone disease in multiple myeloma: from bench to bedside

E Terpos, I Ntanasis-Stathopoulos… - Blood cancer …, 2018 - nature.com
Osteolytic bone disease is the hallmark of multiple myeloma, which deteriorates the quality
of life of myeloma patients, and it affects dramatically their morbidity and mortality. The basis …

Management of endocrine disease: secondary osteoporosis: pathophysiology and management

F Mirza, E Canalis - European journal of endocrinology, 2015 - academic.oup.com
Osteoporosis is a skeletal disorder characterized by decreased mass and compromised
bone strength predisposing to an increased risk of fractures. Although idiopathic …

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised …

N Raje, E Terpos, W Willenbacher, K Shimizu… - The Lancet …, 2018 - thelancet.com
Background Multiple myeloma is characterised by monoclonal paraprotein production and
osteolytic lesions, commonly leading to skeletal-related events (spinal cord compression …

Bone metastases

RE Coleman, J Brown, I Holen - Abeloff's clinical oncology, 2020 - Elsevier
Bone metastasis is a major cause of morbidity in persons with cancer. Complications include
pain, impaired mobility, pathological fracture, spinal cord compression, cranial nerve …

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

E Tian, F Zhan, R Walker, E Rasmussen… - … England Journal of …, 2003 - Mass Medical Soc
Background Myeloma cells may secrete factors that affect the function of osteoblasts,
osteoclasts, or both. Methods We subjected purified plasma cells from the bone marrow of …

IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology

KT Steeve, P Marc, T Sandrine, H Dominique… - Cytokine & growth factor …, 2004 - Elsevier
All osteogenic cells (osteoclasts, osteoblasts) contribute individually to bone remodeling.
Their cellular interactions control their cellular activities and the bone remodeling intensity …

Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease

AE Kearns, S Khosla, PJ Kostenuik - Endocrine reviews, 2008 - academic.oup.com
Osteoclasts and osteoblasts dictate skeletal mass, structure, and strength via their respective
roles in resorbing and forming bone. Bone remodeling is a spatially coordinated lifelong …

Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases

LC Hofbauer, M Schoppet - Jama, 2004 - jamanetwork.com
Bone resorption by osteoclasts is coupled with bone formation by osteoblasts, and this
balanced process continuously remodels and adapts the skeleton. The receptor activator of …

The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling

S Theoleyre, Y Wittrant, SK Tat, Y Fortun… - Cytokine & growth factor …, 2004 - Elsevier
The past decade has seen an explosion in the field of bone biology. The area of bone
biology over this period of time has been marked by a number of key discoveries that have …

Fos/AP‐1 proteins in bone and the immune system

EF Wagner, R Eferl - Immunological reviews, 2005 - Wiley Online Library
The skeleton and the immune system share a variety of different cytokines and transcription
factors, thereby mutually influencing each other. These interactions are not confined to the …